Pancreatic Cancer Metastatic Clinical Trials

15 recruiting

Pancreatic Cancer Metastatic Trials at a Glance

16 actively recruiting trials for pancreatic cancer metastatic are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in New York, Nashville, and Shanghai. Lead sponsors running pancreatic cancer metastatic studies include Azienda Ospedaliera di Padova, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, and Amplia Therapeutics Limited.

Browse pancreatic cancer metastatic trials by phase

Treatments under study

About Pancreatic Cancer Metastatic Clinical Trials

Looking for clinical trials for Pancreatic Cancer Metastatic? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Cancer Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Cancer Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 1

PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

Pancreatic CancerPancreatic Cancer Metastatic
University of California, Irvine18 enrolled1 locationNCT07549958
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled2 locationsNCT07491445
Recruiting
Phase 1Phase 2

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic
Amplia Therapeutics Limited67 enrolled7 locationsNCT07026279
Recruiting
Phase 3

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic
Shanghai Yizhong Pharmaceutical Co., Ltd.416 enrolled2 locationsNCT06752811
Recruiting
Phase 1Phase 2

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Pancreatic Cancer MetastaticAnal Cancer MetastaticSquamous Cell Carcinoma of the Anus Stage Unspecified+1 more
Oncolytics Biotech122 enrolled15 locationsNCT07280377
Recruiting
Phase 2

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic
Fudan University65 enrolled1 locationNCT05969171
Recruiting
Phase 2

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

Colorectal Cancer MetastaticPancreatic Cancer MetastaticPancreatic Cancer Non-resectable
HealthPartners Institute64 enrolled1 locationNCT06605430
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer Metastatic
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center23 enrolled1 locationNCT07040228
Recruiting
Not Applicable

Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.

Pancreatic Cancer MetastaticPancreatic Cancer Non-resectable
Gansu Wuwei Tumor Hospital62 enrolled1 locationNCT06840067
Recruiting
Phase 2

Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver

Pancreatic Cancer Metastatic
Azienda Ospedaliera di Padova56 enrolled1 locationNCT06690528
Recruiting
Phase 2Phase 3

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Pancreatic Ductal AdenocarcinomaPancreatic Cancer Stage IVPancreatic Cancer Metastatic
Panbela Therapeutics, Inc.600 enrolled93 locationsNCT05254171
Recruiting
Phase 2

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

Pancreatic Cancer Metastatic to Liver
Jiang Long40 enrolled1 locationNCT06531278
Recruiting
Phase 1Phase 2

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer

Pancreatic Cancer Metastatic
State University of New York - Downstate Medical Center25 enrolled1 locationNCT06030622
Recruiting
Phase 3

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Stage IVPancreatic Cancer Metastatic
RenJi Hospital401 enrolled6 locationsNCT04674956